Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zafer Sezer

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentNadir Ulu, Daniël Henri Swart, Zafer Sezer, et al.
Vaccines|November 11, 2022
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III TrialMine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, et al.
Vaccines|February 24, 2024
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-UpZafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, et al.
Vaccine|December 2, 2022
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trialsAykut Ozdarendeli, Zafer Sezer, Shaikh Terkis Islam Pavel, et al.
Frontiers in Medicine|May 13, 2025
Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 monthsSeçil Yılmaz, Ahmet Eken, Zafer Sezer, et al.
Vaccines|July 29, 2023
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical StudyIhsan Ates, Ayse Batirel, Mehtap Aydin, et al.
Human Vaccines & Immunotherapeutics|October 31, 2022
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trialAhmet Omma, Ayse Batirel, Mehtap Aydin, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentNadir Ulu, Daniël Henri Swart, Zafer Sezer, et al.
Vaccines|November 11, 2022
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III TrialMine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, et al.
Vaccines|February 24, 2024
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-UpZafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, et al.
Vaccine|December 2, 2022
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trialsAykut Ozdarendeli, Zafer Sezer, Shaikh Terkis Islam Pavel, et al.
Frontiers in Medicine|May 13, 2025
Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 monthsSeçil Yılmaz, Ahmet Eken, Zafer Sezer, et al.
Vaccines|July 29, 2023
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical StudyIhsan Ates, Ayse Batirel, Mehtap Aydin, et al.
Human Vaccines & Immunotherapeutics|October 31, 2022
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trialAhmet Omma, Ayse Batirel, Mehtap Aydin, et al.
Pageof 2